Viral Hepatitis

Latest Articles

Combined Hepatitis A/Typhus Vaccine, Safe and Tolerable For Children

By

Bradley van Paridon

A combined hepatitis A and typhus vaccine in Australia for use in patients aged > 16 years was shown to be well-tolerated in children aged 2 to 16 years.

Besifovir Dipivoxil Maleate Effective, Safe for Long-Term Treatment of Hepatitis B

By

Emily Pond

Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).

Statin Use and Acute Liver Injury Among Veterans With and Without HCV, HIV

By

Bradley van Paridon

Patients using statins had a lower risk for any acute liver injury outcome within 18 months compared with non-users, regardless of HIV and/or hepatitis C virus (HCV) status.

USPSTF Recommends Hep B Screening for Those at Increased Risk

The U.S. Preventive Services Task Force recommends screening adolescents and adults at increased risk for hepatitis B virus infection.

Liver Forum Releases Guidelines for Assessing Patients with NASH

By

Jessica Nye, PhD

The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.

Serologic Markers for Diagnosing Hepatitis E Infection

By

Bradley van Paridon

The persistence of hepatitis E virus (HEV) markers after acute self-limited hepatitis E was assessed and according to the data published in Journal of Viral Hepatitis, the serologic test HEV-Ag performed best overall.

Infective Endocarditis Rates Markedly Increased in Young People With HCV, Opioid Use Disorder

By

Sweta Gupta

In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.

Universal Testing May Help Identify HCV in Pediatric Population

By

Zahra Masoud

New polices, including testing for hepatitis C virus (HCV) during pregnancy, may increase HCV identification in the pediatric population by addressing gaps in maternal HCV testing.

Bundled Rapid HIV/Hep C Testing May Improve Infection Awareness

For people with substance use disorders, combining HIV and hepatitis C virus (HCV) testing and providing immediate test results may increase the number of people who are aware of their infection status.

Hydromorphone Controlled-Release Dispensing Rates May Predict HCV Incidence

By

Zahra Masoud

Compared with all opioid prescriptions, a higher hydromorphone controlled-release dispensing rate was a strong predictor of hepatitis C virus incidence.

Epclusa Approved for Pediatric Patients with Chronic Hepatitis C Infection

By

Brian Park, PharmD

Epclusa is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.

High Rates of SVR Attained With Coblopasvir Plus Sofosbuvir for HCV Infection

By

Virginia A. Schad, PharmD, RPh

In China, researchers investigate the sustained virologic response and safety profile of coblopasvir plus sofosbuvir taken once daily for 12 weeks among patients with HCV genotypes 1, 2, 3, or 6 infections, including individuals with compensated cirrhosis.

Consensus Report for Antiviral Resistance Testing of Hepatitis C Infections

By

Gastroenterology Advisor Contributing Writer

The Public Health England Hepatitis C Virus Resistance Group recommended testing resistance for treatment of the hepatitis C virus by using a genotypic testing method of either the Sanger sequencing or next-generation sequencing methods.

Active Hepatocellular Carcinoma as a Risk Factor for DAA Treatment Failure

By

Gastroenterology Advisor Contributing Writer

Intolerance to treatment with direct acting antiviral treatment was found to be associated with older age and advanced liver disease in patients with hepatocellular carcinoma.

Increasing US Emergency Department Visits Associated With HCV

By

Virginia A. Schad, PharmD, RPh

As emergency departments (EDs) are critical settings for hepatitis C care in the United States, investigators evaluated trends and characteristics of hepatitis C-associated ED visits from 2006 to 2014.

Feasibility of Using HCV-Positive Organs for Heart Transplantation

By

Virginia A. Schad, PharmD, RPh

In a small patient cohort, researchers found that heart transplantation from donors who were hepatitis C virus-positive to recipients without the virus were successful.

Hepatitis C Virus Infection Prevalence in the United States

By

Gastroenterology Advisor Contributing Writer

The prevalence of hepatitis C virus in the US population born after 1985 and Mexican Americans is suggested by researchers to be due to the opioid epidemic.

Novel Combination Therapy Formulation Effectively Treats HCV GT4, Improves Safety Profile

By

Virginia A. Schad, PharmD, RPh

Using data from an Egyptian cohort, investigators sought to determine the safety and efficacy of adding epigallocatechin gallate to sofosbuvir plus daclatasvir with or without ribavirin to treat patients with chronic hepatitis C virus.

Susceptibility for Hepatitis A and B Viruses for People Who Inject Drugs

By

Gastroenterology Advisor Contributing Writer

In Wisconsin, researchers found data that showed people who inject drugs are susceptible to hepatitis A virus infection, and those aged over 35 are susceptible to hepatitis B infection.

DAA Therapies With High SVR12 Safe to Use in Hepatitis C Virus With Low GFR

By

Gastroenterology Advisor Contributing Writer

The study researchers concluded that different DAA therapies may be safely used with high SVR12 rates in patients with HCV and GFR less than 30 ml/min, except for ribavirin due to poor tolerability.